

Literatura ACTA MEDICINAE 13/2018 Farmakologická léčba

- 3 **Terapeutické monitorování sunitinibu**
doc. PharmDr. Jan Juřica, Ph.D. Farmakologický ústav LF MU, Masarykův onkologický ústav, Ústav humánní farmakologie a toxikologie FaF VFU, Brno
PharmDr. Miroslav Turjap, Ph.D. Oddělení klinické farmacie, Ústavní lékárna FN Ostrava
doc. MUDr. Regina Demlová, Ph.D. Farmakologický ústav LF MU, Masarykův onkologický ústav, Brno
- 3 **Imunoterapie karcinomu prsu: nová naděje pro pacientky s pokročilým onemocněním?**
MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno
- 4 **Sekvenční léčba metastatického karcinomu žaludku: trifluridin/tipiracil – budoucí standard třetí linie**
MUDr. Radka Obermannová Ph.D. Klinika komplexní onkologické péče, MOÚ a LF MU, Brno
- 4 **Nové výsledky monoterapie revmatoidní artritidy inhibitorem receptoru IL-6 tocilizumabem**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
Mgr. Lucie Nekvindová Institut biostatistiky a analýz, s. r. o., spin-off LF MU, Brno
Ing. Zlata Křístková Institut biostatistiky a analýz, s. r. o., spin-off LF MU, Brno
- 4 **Sarilumab – výhody v monoterapii**
MUDr. Kristýna Bubová Revmatologický ústav a Revmatologická klinika, 1. LF UK, Praha
- 4 **Diklofenak s duálním uvolňováním v léčbě revmatických chorob**
MUDr. Eva Lokočová | prof. MUDr. Pavel Horák, CSc. | MUDr. Martina Skácelová III. interní klinika – NRE, LF UP a FN Olomouc
- 5 **Secukinumab v léčbě psoriázy, psoriatické artritidy a ankylozující spondylitidy**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 5 **BCL2 v patogenezi a cílené léčbě lymfoproliferací**
doc. MUDr. Pavel Klener jr., Ph.D. I. interní klinika – klinika hematologie VFN a 1. LF UK, Praha
- 5 **Současné možnosti léčby chronické myeloidní leukemie – vybrané otázky**
doc. MUDr. Peter Rohoň, Ph.D. Hemato-onkologická klinika a Ústav Lékařské genetiky FN a LF UP v Olomouci
- 6 **Komentář k systematickému přehledu nepřímo srovnávacímu efektivitě a spotřebě rFVIIIc oproti jiným běžným rFVIII produktům v kontinuální profylaxi u hemofilie A**
MUDr. Ester Zápotocká Klinika dětské hematologie/onkologie, FN Motol, Praha
- 6 **Terapeutické monitorování antiepileptik v těhotenství**
doc. MUDr. Ivana Kaciřová, Ph.D. Ústav klinické farmakologie, LF Ostravské univerzity, Oddělení klinické farmakologie, Ústav laboratorní diagnostiky, FN Ostrava
prof. MUDr. Milan Grundmann, CSc. Ústav klinické farmakologie, LF Ostravské univerzity
- 6 **Patofyziologie migrény v roce 2018**
MUDr. Rudolf Kotas, Ph.D. Neurologická klinika LF UK a FN Plzeň
- 7 **Reverzibilita mechanismu účinku u roztroušené sklerózy**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 7 **Postavení nových perorálních antikoagulancií u invazivních nebo chirurgických výkonů**
doc. MUDr. Tomáš Kvasnička, CSc. Trombotické centrum, ÚLBDL VFN a LF UK, Praha
- 7 **Porovnání klinického efektu převodu z Warfarinu Orion 3 mg na Warfarin PMCS 2 mg/5 mg**
MUDr. Petr Magrot Ambulance OKB Lab, a. s., Praha
- 7 **Lercanidipin: příznivé farmakologické vlastnosti jako předpoklad terapeutické účinnosti, bezpečnosti a vysoké compliance nemocných**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 8 **Fixní kombinace perindoprilu, amlodipinu a indapamidu**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 8 **Význam eozinofilů jako diagnostického a prediktivního biomarkeru; algoritmy léčby těžkého astmatu v době personalizované medicíny**
doc. MUDr. Jaromír Bystroň, CSc. Oddělení alergologie a klinické imunologie FN Olomouc

- 8 **Cefprozil versus klarithromycin v léčbě exacerbace chronické bronchitidy**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 9 **Studie ACTIVATE: účinek aclidinium/formoterolu na plicní hyperinflaci, výkonnost a fyzickou aktivitu u pacientů s chronickou obstrukční plicní nemocí**
MUDr. Zuzana Perná Plicní ambulance, Medicon a.s., Praha
- 9 **Farmakologická léčba hyperaktivního močového měchýře**
MUDr. Alexandra Gregušová | MUDr. Zuzana Kachlířová Urologická klinika 3. LF UK a FN Královské Vinohrady, Praha
- 9 **Léčba Pompeho nemoci**
doc. MUDr. Martin Magner, Ph.D. | MUDr. Jitka Jirečková Klinika dětského a dorostového lékařství, 1. LF UK a VFN, Praha
- 9 **Konzervativní léčba glaukomu**
doc. MUDr. Eva Růžičková, CSc. Oční klinika 1. LF UK a VFN, Praha

Terapeutické monitorování sunitinibu

doc. PharmDr. Jan Juřica, Ph.D. Farmakologický ústav LF MU, Masarykův onkologický ústav, Ústav humánní farmakologie a toxikologie FaF VFU, Brno

PharmDr. Miroslav Turjap, Ph.D. Oddělení klinické farmacie, Ústavní lékárna FN Ostrava

doc. MUDr. Regina Demlová, Ph.D. Farmakologický ústav LF MU, Masarykův onkologický ústav, Brno

- 1 Group EESNW: Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2014, 25, suppl. 3, s. iii21–26.
- 2 Escudier, B. – Porta, C. – Schmidinger, M., et al.: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2016, 27, suppl. 5, s. v58–v68.
- 3 Lankheet, N. – Desai, I. – Mulder, S., et al.: Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. *Br J Clin Pharmacol*, 2017, 83, s. 2195–2204.
- 4 Gotta, V. – Widmer, N. – Decosterd, L. A., et al.: Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. *Cancer Chemother Pharmacol*, 2014, 74, s. 1307–1319.
- 5 Larson, R. A. – Druker, B. J. – Guilhot, F., et al.: Group IRIVS: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. *Blood*, 2008, 111, s. 4022–4028.
- 6 Blasdel, C. – Egorin, M. J. – Lagattuta, T. F., et al.: Therapeutic drug monitoring in CML patients on imatinib. *Blood*, 2007, 110, s. 1699–1701.
- 7 Guo, F. – Letrent, S. P. – Munster, P. N., et al.: Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. *Cancer Chemother Pharmacol*, 2008, 62, s. 97–109.
- 8 Dynamed American Society of Health System Pharmacists I: *Dynamed*. In. 03-2017 edn. Ipswich (MA): EBSCO Information Services. 1995–2017; 2017.
- 9 Schmid, T. A. – Gore, M. E.: Sunitinib in the treatment of metastatic renal cell carcinoma. *Ther Adv Urol*, 2016, 8, s. 348–371.
- 10 Papaetis, G. S. – Syrigos, K. N.: Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. *Bio Drugs*, 2009, 23, s. 377–389.
- 11 Motzer, R. J. – Jonasch, E. – Agarwal, N., et al.: Kidney Cancer, Version 4.2018, NCCN Clinical Practice Guidelines in Oncology. *National Comprehensive Cancer Network*, 2018, 4, s. 1–62.
- 12 von Mehren, M. – Randall, R. L. – Benjamin, R. S., et al.: Soft Tissue Sarcoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 2017, s. 1–137.
- 13 Pfizer: SmPC, Sutent. In. Edited by Agency EM; 2016, 67.
- 14 Di Gion, P. – Kanefendt, F. – Lindauer, A., et al.: Clinical Pharmacokinetics of tyrosine kinase inhibitors focus on pyrimidines, pyridines and pyrroles. *Clinical Pharmacokinetics*, 2011, 50, s. 551–603.
- 15 Yu, H. – Steeghs, N. – Kloth, J. S., et al.: Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. England: 2014 The British Pharmacological Society. *Br J Clin Pharmacol*, 2015, 79, s. 809–819.
- 16 Yu, H. – Steeghs, N. – Nijenhuis, C. M., et al.: Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. *Clin Pharmacokinet*, 2014, 53, s. 305–325.
- 17 de Wit, D. – van Erp, N. P. – Khosravan, R., et al.: Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. *Bmc Cancer*, 2014, 14.
- 18 Noda, S. – Otsuji, T. – Baba, M., et al.: Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. *Clin Genitourin Cancer*, 2015, 13, s. 350–358.
- 19 Terada, T. – Noda, S. – Inui, K., et al.: Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. *Pharmacol Ther*, 2015, 152, s. 125–134.
- 20 Bracarda, S. – Iacovelli, R. – Boni, L., et al.: Sunitinib administered on Z1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. *Ann Oncol*, 2016, 27, s. 366.
- 21 Lee, J. L. – Kim, M. K. – Park, I., et al.: Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. *Ann Oncol*, 2015, 26, s. 2300–2305.
- 22 George, S. – Blay, J. Y. – Casali, P. G., et al.: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. *Eur J Cancer*, 2009, 45, s. 1959–1968.
- 23 Eisen, T. – Sternberg, C. N. – Robert, C., et al.: Targeted therapies for renal cell carcinoma: review of adverse event management strategies. *J Natl Cancer Inst*, 2012, 104, s. 93–113.
- 24 Pfizer: SmPC, Sutent. In. Edited by Agency EM; 2016, 67.
- 25 Motzer, R. J. – Hutson, T. E. – Tomczak, P., et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 115–124.
- 26 Houk, B. E. – Bello, C. L. – Poland, B., et al.: Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. *Cancer Chemotherapy and Pharmacology*, 2010, 66, s. 357–371.
- 27 Lankheet, N. A. G. – Knapen, L. M. – Schellens, J. H. M., et al.: Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. *Therapeutic Drug Monitoring*, 2014, 36, s. 326–334.
- 28 Faivre, S. – Delbaldo, C. – Vera, K., et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *J Clin Oncol*, 2006, 24, s. 25–35.
- 29 Britten, C. D. – Kabbinavar, F. – Hecht, J. R., et al.: A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. *Cancer Chemother Pharmacol*, 2008, 61, s. 515–524.
- 30 de Wit, D. – Guchelaar, H. J. – den Hartigh, J., et al.: Individualized dosing of tyrosine kinase inhibitors: are we there yet? *Drug Discov Today*, 2015, 20, s. 18–36.
- 31 Sabanathan, D. – Zhang, A. – Fox, P., et al.: Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring. *Cancer Chemother Pharmacol*, 2017, 80, s. 385–393.
- 32 Demetri, G. D. – Heinrich, M. C. – Fletcher, J. A., et al.: Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. *Clin Cancer Res*, 2009, 15, s. 5902–5909.
- 33 Lankheet, N. A. – Kloth, J. S. – Gadella-van Hooijdonk, C. G., et al.: Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. *Br J Cancer*, 2014, 110, s. 2441–2449.
- 34 Teo, Y. L. – Chue, X. P. – Chau, N. M., et al.: Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. *Targeted Oncol*, 2015, 10, s. 429–437.
- 35 Liu, X. – Fiocco, M. – Swen, J. J., et al.: Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. *Acta Oncol*, 2017, 56, s. 582–589.
- 36 Houk, B. E. – Bello, C. L. – Michaelson, M. D., et al.: A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC). *EJC Supplements*, 2007, 5, s. 300.
- 37 Mizuno, T. – Fukudo, M. – Terada, T., et al.: Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. *Drug Metab Pharmacokinet*, 2012, 27, s. 631–639.
- 38 Keil, C. – Götz, L. – Olbert, P., et al.: Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. *Urologe A*, 2015, 54, s. 811–818.
- 39 Teo, Y. – Chue, X. – Chau, N., et al.: Association of drug exposure with clinical response and toxicities in metastatic renal cell carcinoma patients (mRCC) receiving an alternative dosing (AD) regimen of sunitinib. *J Clin Oncol*, 2013, 31.
- 40 Mendel, D. B. – Laird, A. D. – Xin, X., et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. *Clin Cancer Res*, 2003, 9, s. 327–337.
- 41 Ljungberg, B. – Bensalah, K. – Bex, A., et al.: EAU guidelines on renal cell carcinoma. *Eur Assoc Urol*, 2018, s. 1–62.
- 42 Uemura, H. – Shinohara, N. – Yuasa, T., et al.: A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. *Jpn J Clin Oncol*, 2010, 40, s. 194–202.
- 43 Narjoz, C. – Cessot, A. – Thomas-Schoemann, A., et al.: Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. *Invest New Drugs*, 2015, 33, s. 257–268.
- 44 Nagata, M. – Ishiwata, Y. – Takahashi, Y., et al.: Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma. *Biol Pharm Bull*, 2015, 38, s. 402–410.
- 45 Kloth, J. S. – Klumpen, H. J. – Yu, H., et al.: Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. *Clin Pharmacokinet*, 2014, 53, s. 261–269.
- 46 Bello, C. L. – Mulay, M. – Huang, X., et al.: Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib. *Clin Cancer Res*, 2009, 15, s. 7045–7052.
- 47 Gurney, H.: Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. *J Clin Oncol*, 1996, 14, s. 2590–2611.
- 48 Rini, B. – Cohen, D. – Lu, D., et al.: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. *J Nat Cancer Institute*, 2011, 103, s. 763–773.
- 49 Klumpen, H. – Samer, C. – Mathijssen, R., et al.: Moving towards dose individualization of tyrosine kinase inhibitors. *Cancer Treatment Reviews*, 2011, 37, s. 251–260.
- 50 Kollmannsberger, C. – Soulieres, D. – Wong, R., et al.: Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. *Canad Urol Assoc J*, 2007, 1, s. S41–S54.
- 51 Yuasa, T. – Takahashi, S. – Hatake, K., et al.: Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. *Cancer Sci*, 2011, 102, s. 1949–1957.

Imunoterapie karcinomu prsu: nová naděje pro pacientky s pokročilým onemocněním?

MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno

- 1 Loi, S. – Giobbie-Hurder, A. – Gombos, A., et al.: Phase II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive advanced breast cancer: results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014). Prezentováno na 2017 San Antonio Breast Cancer Symposium, 5.–9. 12. 2017, San Antonio, TX, abstrakt GS2-06.
- 2 den Brok, W. D. – Speers, C. H. – Gondara, L. – Baxter, E., et al.: Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. *Breast Cancer Res Treat*, 2017, 161, s. 549–556.
- 3 Bonotto, M. – Gerratana, L. – Poletto, E., et al.: Measures of outcome in metastatic breast cancer: in sights from a real-world scenario. *Oncologist*, 2014, 19, s. 608–615.
- 4 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology – breast cancer.V1. 2018. Dostupné z: https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf, vyhledáno 16. 11. 2018.
- 5 Nanda, R., et al.: Pembrolizumab in patients with advanced triple-negative breast cancer: phase II KEYNOTE-012 study. *J Clin Oncol*, 2016, 34, s. 2460–2467.
- 6 Adams, S., et al.: Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. 2017.
- 7 Adams, S., et al.: Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. 2017.
- 8 Schmid, P., et al.: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *New Eng J Med*, 2018, DOI: 10.1056/NEJMoa1809615.
- 9 Adams, S., et al.: Safety and clinical activity of atezolizumab (anti-PD-L1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. *J Clin Oncol Off J Am Soc Clin Oncol*, 2016, 34.

Sekvenční léčba metastatického karcinomu žaludku: trifluridin/tipiracil – budoucí standard třetí linie

MUDr. Radka Obermannová Ph.D. Klinika komplexní onkologické péče, MOÚ a LF MU, Brno

- 1 Lordick, F. – Allum, W. – Carneiro, F., et al.: Unmet needs and challenges in gastric cancer: the way forward. *Cancer Treat Rev*, 2014, 40, s. 692–700.
- 2 Bang, Y. J. – Van Cutsem, E. – Feyereislova, A., et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*, 2010, 376, s. 687–697.
- 3 Guimbaud, R. – Louvet, C. – Ries, P., et al.: Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study. *J Clin Oncol*, 2014, 32, s. 3520–3526.
- 4 Fuchs, C. S. – Tomasek, J. – Yong, C. J., et al.: Ramucicirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*, 2014, 383, s. 31–39.
- 5 Wilke, H. – Muro, K. – Van Cutsem, E., et al.: Ramucicirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 1224–1235.
- 6 Mayer, R. J. – Van Cutsem, E. – Falcone, A., et al.: Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECURSE). *N Engl J Med*, 2015, 372, s. 1909–1919.
- 7 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*, 2014, 513, s. 202–209.
- 8 Taberero, J., et al.: ESMO GI, 2018, abstrakt LBA-002.

Nové výsledky monoterapie revmatoidní artritidy inhibitorem receptoru IL-6 tocilizumabem

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

Mgr. Lucie Nekvindová Institut biostatistiky a analýz, s. r. o., spin-off LF MU, Brno

Ing. Zlata Křístková Institut biostatistiky a analýz, s. r. o., spin-off LF MU, Brno

- 1 Smolen, J. S. – Landewé, R. – Bijlsma, J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
- 2 Šenolt, L. – Mann, H. – Závada, J. – Pavelka, K. – Vencovský, J.: Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. *Česká revmatologie*, 2017, 1, s. 8–24.
- 3 García Vicuna, R. – Martín-Martínez, M. A. – Gonzales-Crespo, M. R., et al.: Recommendations by the Spanish Rheumatology Society for the management of patients with rheumatoid arthritis who cannot be treated with methotrexate. *Rheumatol Clin*, 2017, 13, s. 127–138.
- 4 Ogata, A. – Tanimura, K. – Sugimoto, T., et al.: Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. *Arthritis Care Res (Hoboken)*, 2014, 66, s. 344–354.
- 5 Choy, E. – Caporali, R. – Xavier, R., et al.: Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-Framework phase 4 study programme TOZURA conducted in 22 countries. *Rheumatology*, doi:10.1093/rheumatology/keu443.
- 6 Dougados, M. – Kissel, K. – Sheeran, T., et al.: Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Ann Rheum Dis*, 2013, 72, s. 43–50, doi:10.1136/annrheumdis-2011-20128.
- 7 Bykerk, V. P. – Östör, A. J. K. – Alvaro-Gracia, J., et al.: Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. *Ann Rheum Dis*, 2012, 71, s. 1950–1954.
- 8 Gabay, C. – Riek, M. – Hetland, M. L., et al.: Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. *Ann Rheum Dis*, 2016, 75, s. 1336–1342, doi:10.1136/annrheumdis-2015-207760.
- 9 Gabay, C. – Emery, P. – van Vollenhoven, R., et al.: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet*, 2013, 381, s. 1541–1550.
- 10 Choy, E. H. – Bernasconi, C. – Aassi, M., et al.: Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic in a global comparative observational study. *Arthritis Care Res (Hoboken)*, 2017, 11, s. 475–476.
- 11 Lauper, K. – Nordström, D. C. – Pavelka, K., et al.: Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. *Ann Rheum Dis*, 2018, 77, s. 1276–1282.
- 12 Smolen, J. S. – van der Heijde, D. – Machold, K. P., et al.: Proposal for a new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis*, 2014, 73, s. 3–5.
- 13 Jones, G. – Sebba, A. – Gu, J., et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis*, 2010, 69, s. 88–96.
- 14 Burmester, G. R. – Mariette, X. – Montecucco, C., et al.: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. *Ann Rheum Dis*, 2007, 66, s. 732–739.

Sarilumab – výhody v monoterapii

MUDr. Kristýna Bubová Revmatologický ústav a Revmatologická klinika, 1. LF UK, Praha

- 1 Šenolt, L. – Mann, H. – Závada, J. – Pavelka, K. – Vencovský, J.: Doporučení České revmatologické společnosti ČLS JEP pro farmakoterapii revmatoidní artritidy 2017. *Čes Revmatol*, 2017, 25, s. 8–24.
- 2 Yoshida, Y. – Tanaka, T.: Interleukin 6 and rheumatoid arthritis. *Biomed Res Int*, 2014, 2014, 698313.
- 3 Schinnerling, K. – Aguilón, J. C. – Catalán, D., et al.: The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. *Clin Exp Immunol*, 2017, 189, s. 12–20.
- 4 Hirano, T. – Matsuda, T. – Turner, M., et al.: Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. *Eur J Immunol*, 1988, 18, s. 1797–1801.
- 5 Dasgupta, B. – Corkill, M. – Kirkham, B., et al.: Serials himation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. *J Rheumatol*, 1992, 19, s. 22–25.
- 6 Huizinga, T. W. – Fleischmann, R. M. – Jasson, M., et al.: Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. *Ann Rheum Dis*, 2013, 73, s. 1626–1634.
- 7 Genovese, M. C. – Fleischmann, R. – Kivitz, A. J., et al.: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol*, 2015, 67, s. 1424–1437.
- 8 Strand, V. – Reaney, M. – Chen, C., et al.: Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. *RMD Open*, 2017, 3, s. e000416, doi: 10.1136/rmdopen-2016-000416.
- 9 Burmester, G. R. – Lin, Y. – Patel, R., et al.: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*, 2017, 76, s. 840–847.

Diklofenak s duálním uvolňováním v léčbě revmatických chorob

MUDr. Eva Lokočová | prof. MUDr. Pavel Horák, CSc. | MUDr. Martina Skácelová III. interní klinika – NRE, LF UP a FN Olomouc

- 1 Fowler, P. D. – Shadforth, M. F. – Crook, P. R., et al.: Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long – term treatment of rheumatoid arthritis. *Eur J Clin Pharmacol*, 1983, 25, s. 389–394.
- 2 Sioufi, A. – Schoeller, J. P. – Schwarzberg, C., et al.: Presence of diclofenac in plasma and in synovial fluid in various rheumatic disorders. *Gaz Med Fr*, 1984.
- 3 Benson, M., et al.: Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis. *Semin Arthritis Rheum*, 1985, 15, suppl. 1.
- 4 Costa, B. R. – Reichenbach, S. – Keller, N., et al.: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. *Lancet*, 2017, 390, s. e211–e233.
- 5 Pavelka, K.: A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. *Curr Med Res Opin*, 2012, 28, s. 163–178.
- 6 Schmitt, W., et al.: Clinical trial on the efficacy and safety of different diclofenac formulations: multiple-unit formulations compared to enteric coated tablets in patients with activated osteoarthritis. *Inflammopharmacology*, 1999, 7, s. 363–375.
- 7 Wallace, J. L. – Syer, S. – Denou, L. E., et al.: Proton pump inhibitors and low-dose aspirin markedly exacerbate NSAID-induced small intestinal injury: link to dysbiosis? *Gastroenterology*, 2011, 141, s. 1314–1322.
- 8 Sriuttha, P. – Sirichanchuen, B. – Permsuwan, U.: Hepatotoxicity of nonsteroidal anti-inflammatory drugs: A systematic review of randomized controlled trials. *Int J Hepatol*, 2018, 5253623, 13, doi: 10.1155/2018/5253623.
- 9 Rubenstein, J. H. – Laine, L.: Systematic review: The hepatotoxicity of non-steroidal anti-inflammatory drugs. *Aliment Pharmacol Ther*, 2004, 20, s. 373–380.
- 10 Schmidt, M.: Diclofenac use and cardiovascular risks: series of nationwide cohort studies. *BMJ*, 2018, 362, doi: https://doi.org/10.1136/bmj.k3426.

Secukinumab v léčbě psoriázy, psoriatické artritidy a ankylozující spondylitidy

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Lonnberg, A. S. – Zachariae, C. – Skov, L.: Targeting of interleukin-17 in the treatment of psoriasis. *Clin Cosmet Investig Dermatol*, 2014, 7, s. 251–259.
- 2 Sanford, M. – McKeage, K.: Secukinumab: first global approval. *Drugs*, 2015, 75, s. 329–338.
- 3 SPC: Cosentyx. Dostupné z: https://ec.europa.eu/health/documents/community-register/2015/20150115130444/anx_130444_en.pdf, vyhledáno 30. 11. 2018.
- 4 Roman, M. – Madkan, V. K. – Chiu, M. W.: Profile of secukinumab in the treatment of psoriasis: current perspectives. *Ther Clin Risk Manag*, 2015, 11, s. 1767–1777.
- 5 Dragatin, C. – Polus, F. – Bodenlenz, M., et al.: Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion. *Exp Dermatol*, 2016, 25, s. 157–159.
- 6 Langley, R. G. – Elewski, B. E. – Lebwohl, M., et al.: Secukinumab in plaque psoriasis—results of two phase 3 trials. *N Engl J Med* 2014; 371, s. 326–338.
- 7 Blauvelt, A. – Prinz, J. C. – Gottlieb, A. B., et al.: Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). *Br J Dermatol*, 2015, 172, s. 484–493.
- 8 Paul, C. – Lacour, J. P. – Tedremets, L., et al.: Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). *J Eur Acad Dermatol Venereol*, 2015, 29, s. 1082–1090.
- 9 Mrowietz, U. – Leonardi, C. L. – Girolomoni, G., et al.: Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). *J Am Acad Dermatol*, 2015, 73, s. 27–36.
- 10 Thaci, D. – Humeniuk, J. – Frambach, Y., et al.: Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). *Br J Dermatol*, 2015, 173, s. 777–787.
- 11 Blauvelt, A. – Reich, K. – Tsai, T. F., et al.: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. *J Am Acad Dermatol*, 2017, 76, s. 60–69.
- 12 Strand, V. – Mease, P. – Gossec, L., et al.: Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomized phase III trial (FUTURE 1). *Ann Rheum Dis*, 2017, 76, s. 203–207.
- 13 McInnes, I. B. – Mease, P. J. – Kirkham, B., et al.: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2015, 386, s. 1137–1146.
- 14 Mease, P. J. – Kavanaugh, A. – Reimold, A., et al.: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. *MDM Open*, 2018, 4, e000723.
- 15 Nash, P. – Mease, P. J. – McInnes, I. B., et al.: Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). *Arthritis Res Ther*, 2018, 20, s. 47.
- 16 Mease, P. – van der Heijde, D. – Landewe, R., et al.: Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Ann Rheum Dis*, 2018, 77, s. 890–897.
- 17 Baeten, D. – Baraliakos, X. – Braun, J., et al.: Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet*, 2013, 382, s. 1705–1713.
- 18 Baeten, D. – Sieper, J. – Braun, J., et al.: Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. *N Engl J Med*, 2015, 373, s. 2534–2548.
- 19 Sieper, J. – Deodhar, A. – Marzo-Ortega, H., et al.: Secukinumab efficacy in anti-TNF-naïve and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. *Ann Rheum Dis*, 2017, 76, s. 571–592.
- 20 Baraliakos, X. – Kivitz, A. – Deodhar, A. A., et al.: Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. *Clin Exp Rheumatol*, 2018, 36, s. 50–55.
- 21 Pavelka, K. – Kivitz, A. – Dokoupilova, E., et al.: Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. *Arthritis Res Ther*, 2017, 19, s. 285.
- 22 Chioato, A. – Nosedà, E. – Stevens, M., et al.: Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. *Clin Vaccine Immunol*, 2012, 19, s. 1597–1602.

BCL2 v patogenezi a cílené léčbě lymfoproliferací

doc. MUDr. Pavel Klener jr., Ph.D. I. interní klinika – klinika hematologie VFN a 1. LF UK, Praha

- 1 Kerr, J. F. – Wyllie, A. H. – Currie, A. R.: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *British Journal of Cancer*, 1972, 26, s. 239–257.
- 2 Elmore, S.: Apoptosis: a review of programmed cell death. *Toxicologic Pathology*, 2007, 35, s. 495–516.
- 3 Adams, J. M. – Cory, S.: The BCL-2 arbiters of apoptosis and their growing role as cancer targets. *Cell Death and Differentiation*, 2018, 25, s. 27–36.
- 4 Wu, H. – Medeiros, L. J. – Young, K. H.: Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignancies. *Blood Reviews*, 2018, 32, s. 8–28.
- 5 Chipuk, J. E. – Moldoveanu, T. – Llambi, F., et al.: The BCL-2 family member, Bcl-2, is a tumor suppressor. *Molecular Cell*, 2010, 37, s. 299–310.
- 6 Elkholi, R. – Floros, K. V. – Chipuk, J. E.: The role of BH3-only proteins in tumor cell development, signaling, and treatment. *Genes & Cancer*, 2011, 2, s. 523–537.
- 7 Fukuhara, S. – Rowley, J. D. – Variakojis, D., et al.: Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. *Cancer Research*, 1979, 39, s. 3119–3128.
- 8 Levine, E. G. – Arthur, D. C. – Frizzera, G., et al.: There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. *Blood*, 1985, 66, s. 1414–1422.
- 9 Nunez, G. – Seto, M. – Seremetis, S., et al.: Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, s. 4589–4593.
- 10 Devan, J. – Janikova, A. – Mraz, M.: New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs. *Semin Oncol*, 2018, pii, S0093-7754(17)30128-8
- 11 Tsuyama, N. – Sakata, S. – Baba, S., et al.: BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. *Blood*, 2017, 130, s. 489–500.
- 12 Klanova, M. – Andera, L. – Brazina, J., et al.: Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. *Clin Cancer Res*, 2016, 22, s. 1138–1149.
- 13 Palamarchuk, A. – Efanov, A. – Nazaryan, N., et al.: 13q14 deletions in CLL involve cooperating tumor suppressors. *Blood*, 2010, 115, s. 3916–3922.
- 14 Davids, M. S.: Targeting BCL-2 in B-cell lymphomas. *Blood*, 2017, 130, s. 1081–1088.
- 15 Touzeau, C. – Maciag, P. – Amiot, M., et al.: Targeting Bcl-2 for the treatment of multiple myeloma. *Leukemia*, 2018, 32, s. 1899–1907.
- 16 Montero, J. – Letai, A.: Why do BCL-2 inhibitors work and where should we use them in the clinic? *Cell Death and Differentiation*, 2018, 25, s. 56–64.
- 17 Tarhini, A. A. – Kirkwood, J. M.: Oblimersen in the treatment of metastatic melanoma. *Future Oncology* (London), 2007, 3, s. 263–271.
- 18 Fulda, S. – Galluzzi, L. – Kroemer, G.: Targeting mitochondria for cancer therapy. *Nature Reviews Drug Discovery*, 2010, 9, s. 447–464.
- 19 Mason, K. D. – Khaw, S. L. – Rayeroux, K. C., et al.: The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. *Leukemia*, 2009, 23, s. 2034–2041.
- 20 Schoenwaelder, S. M. – Jarman, K. E. – Gardiner, E. E., et al.: Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. *Blood*, 2011, 118, s. 1663–1674.
- 21 Souers, A. J. – Leverson, J. D. – Boghaert, E. R., et al.: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nature Medicine*, 2013, 19, s. 202–208.
- 22 Roberts, A. W. – Davids, M. S. – Pagel, J. M., et al.: Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. *The New England Journal of Medicine*, 2016, 374, s. 311–322.
- 23 Deeks, E. D.: Venetoclax: first global approval. *Drugs*, 2016, 76, s. 979–987.
- 24 Davids, M. S. – Roberts, A. W. – Seymour, J. F., et al.: Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 2017, 35, s. 826–833.
- 25 Tam, C. S. – Anderson, M. A. – Pott, C., et al.: Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. *The New England Journal of Medicine*, 2018, 378, s. 1211–1223.
- 26 Seymour, J. F. – Kipps, T. J. – Eichhorst, B., et al.: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *The New England Journal of Medicine*, 2018, 378, s. 1107–1120.
- 27 de Vos, S. – Swinnen, L. J. – Wang, D., et al.: Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 2018, 29, s. 1932–1938.
- 28 Opferman, J. T. – Kothari, A.: Anti-apoptotic BCL-2 family members in development. *Cell Death and Differentiation*, 2018, 25, s. 37–45.

Současné možnosti léčby chronické myeloidní leukemie – vybrané otázky

doc. MUDr. Peter Rohoň, Ph.D. Hemato-onkologická klinika a Ústav lékařské genetiky FN a LF UP v Olomouci

- 1 Arber, D. A. – Orazi, A. – Hasserjian, R., et al.: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*, 2016, 127, s. 2391–2405.
- 2 Huang, X. – Cortes, J. – Kantarjian, H.: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. *Cancer*, 2012, 118, s. 3123–3127.
- 3 Jabbour, E. – Kantarjian, H.: Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. *Am J Hematol*, 2018, 93, s. 442–459.
- 4 Deininger, M. W. – Goldman, J. M. – Melo, J. V.: The molecular biology of chronic myeloid leukemia. *Blood*, 2000, 96, s. 3343–3356.
- 5 Radich, J. P. – Deininger, M. – Abboud, C. N., et al.: Chronic Myeloid Leukemia, Version 1.2019. *J Natl Compr Canc Net*, 2018, 16, s. 1108–1135.
- 6 Hochhaus, A. – Larson, R. A. – Guilhot, F., et al.: Long-term outcomes of imatinib treatment for chronic myeloid leukemia. *N Engl J Med*, 2017, 376, s. 917–927.
- 7 Hochhaus, A. – Saglio, G. – Hughes, T. P., et al.: Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia*, 2016, 30, s. 1044–1054.
- 8 Cortes, J. E. – Saglio, G. – Kantarjian, H. M., et al.: Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. *J Clin Oncol*, 2016, 34, s. 2333–2340.
- 9 Cortes, J. E. – Gambacorti-Passerini, C. – Deininger, M. W., et al.: Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. *J Clin Oncol*, 2018, 36, s. 231–237.
- 10 Baccarani, M. – Deininger, M. W. – Rosti, G., et al.: European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, 2013, 122, s. 872–884.
- 11 Steegmann, J. L. – Baccarani, M. – Breccia, M., et al.: European Leukemia Net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia*, 2016, 30, s. 1648–1671.
- 12 Efficace, F. – Baccarani, M. – Breccia, M., et al.: Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. *Leukemia*, 2013, 27, s. 1511–1519.
- 13 Berman, E. – Girotra, M. – Cheng, C., et al.: Effect of long term

- imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. *Leuk Res*, 2013, 37, s. 790–794.
- 14 Giles, F. J. – Mauro, M. J. – Hong, F., et al.: Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. *Leukemia*, 2013, 27, s. 1310–1315.
 - 15 Porkka, K. – Khoury, H. J. – Paquette, R. L., et al.: Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. *Cancer*, 2010, 116, s. 377–386.
 - 16 Montani, D. – Bergot, E. – Gunther, S., et al.: Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation*, 2012, 125, s. 2128–2137.
 - 17 Muller, M. C. – Cervantes, F. – Hjorth-Hansen, H., et al.: Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. *Crit Rev Oncol Hematol*, 2017, 120, s. 52–59.
 - 18 Etienne, G. – Guilhot, J. – Rea, D., et al.: Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. *J Clin Oncol*, 2017, 35, s. 298–305.
 - 19 Ross, D. M. – Masszi, T. – Gomez Casares, M. T., et al.: Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontone nilotinib: 96-week update of the ENEST freedom study. *J Cancer Res Clin Oncol*, 2018, 144, s. 945–954.
 - 20 Okada, M. – Imagawa, J. – Tanaka, H., et al.: Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. *Clin Lymphoma Myeloma Leuk*, 2018, 18, s. 353–360.
 - 21 Ross, D. M. – Branford, S. – Seymour, J. F., et al.: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. *Blood*, 2013, 122, s. 515–522.
 - 22 Ilander, M. – Olsson-Stromberg, U. – Schlums, H., et al.: Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. *Leukemia*, 2017, 31, s. 1108–1116.
 - 23 Saussele, S. – Richter, J. – Guilhot, J., et al.: Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. *Lancet Oncol*, 2018, 19, s. 747–757.
 - 24 Lee, S. E. – Choi, S. Y. – Song, H. Y., et al.: Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. *Haematologica*, 2016, 101, s. 717–723.

Komentář k systematickému přehledu nepřímo srovnávajícímu efektivitu a spotřebu rFVIIIc oproti jiným běžným rFVIII produktům v kontinuální profylaxi u hemofilie A

MUDr. Ester Zápotocká Klinika dětské hematologie/onkologie, FN Motol, Praha

- 1 Mahangu, J. – Powell, J. S. – Ragni, M. V., et al.: Phase 3 study of recombinant factor VIIIc fusion protein in severe hemophilia A. *Blood*, 2014, 123, s. 317–325.
- 2 Iorio, A. – Krishnan, S. – Mirén, K. J., et al.: Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII FC fusion protein and conventional recombinant factor VIII products. *Haemophilia*, 2017, 23, s. 408–416.
- 3 Tarantino, M. D. – Collins, P. W. – Hay, C. R., et al.: Clinical evaluation of an advanced category antihemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. *Haemophilia*, 2004, 10, s. 428–437.
- 4 Shapiro, A. D.: Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. *Vasc Health Risk Manag*, 2007, 3, s. 555–565.
- 5 Valentino, L. A. – Mamonov, V. – Hellmann, A., et al.: A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. *J Thromb Haemost*, 2012, 10, s. 359–367.
- 6 Reicht, M. – Nemes, L. – Matysiak, M., et al.: Clinical evaluation of moroctocog alfa (AFCC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of hemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII (study 1). *Haemophilia*, 2009, 15, s. 869–880.
- 7 Lentz, S. R. – Misgav, M. – Ozelo, M., et al.: Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe hemophilia A: safety and efficacy. *Haemophilia*, 2013, 19, s. 691–697.
- 8 Tiede, A. K. – Oldenburg, J. – Bichler, J.: Consumption of FVIII concentrate during on-demand prophylactic treatment with human-cl rFVIII In prospective clinical studies in adult patients with severe hemophilia A. 55th ASH Annual Meeting and Exposition, 7.–10. 12. 2013; New Orleans, LA, 2013.
- 9 Pollmann, H. – Externest, D. – Ganser, A., et al.: Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with hemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. *Haemophilia*, 2007, 13, s. 131–143.

Terapeutické monitorování antiepileptik v těhotenství

doc. MUDr. Ivana Kacířová, Ph.D. Ústav klinické farmakologie, LF Ostravské univerzity, Oddělení klinické farmakologie, Ústav

laboratorní diagnostiky, FN Ostrava

prof. MUDr. Milan Grundmann, CSc. Ústav klinické farmakologie, LF Ostravské univerzity

- 1 Meadow, S. R.: Anticonvulsant drugs and congenital abnormalities. *Lancet*, 1968, 2, s. 1296.
- 2 Galappathy, P. – Liyanage, C. K. – Lucas, M. N., et al.: Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study. *BMC Pregnancy Childbirth*, 2018, 18, s. 230.
- 3 Tomson, T. – Battino, D. – Bonizzoni, E., et al.: EURAP Study Group: Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. *Lancet Neurol*, 2018, 17, s. 530–538.
- 4 Vajda, F. J. E. – O'Brien, T. J. – Graham, J. E., et al.: Antiepileptic drug polytherapy in pregnant women with epilepsy. *Acta Neurol Scand*, 2018, 138, s. 115–121.
- 5 Vajda, F. J. E. – O'Brien, T. J. – Graham, J. E., et al.: Valproate-associated foetal malformations-Rates of occurrence, risks in attempted avoidance. *Acta Neurol Scand*, 14. 8. 2018.
- 6 Sabers, A. – Tomson, T.: Managing antiepileptic drugs during pregnancy and lactation. *Curr Opin Neurol*, 2009, 22, s. 157–161.
- 7 Tomson, T. – Battino, D.: Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. *Clin Pharmacokinet*, 2007, 46, s. 209–219.
- 8 Kacířová, I. – Grundmann, M. – Broznanová, H.: Léková interakce mezi lamotriginem a kyselínou valproovou užívanými při porodu a během kojení. *Klin Farmakol Farm*, 2010, 24, s. 222–225.
- 9 Tomson, T.: Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. *Ther Drug Monit*, 2005, 27, s. 718–721.
- 10 Pennell, P. B. – Hovinga, C. A.: Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokinetics. *Int Rev Neurobiol*, 2008, 83, s. 227–240.
- 11 Richards, N. – Reith, D. – Stitely, M. – Smith, A.: Are doses of lamotrigine or levetiracetam adjusted during pregnancy? *Epilepsia Open*, 2018, 3, s. 86–90.
- 12 Kacířová, I. – Grundmann, M. – Kořistková, B. – Broznanová, H.: Development of a treatment of pregnant women suffering from epilepsy in the region of Ostrava between the years 1991 and 1996. *Čes Slov Farm*, 2010, 59, s. 172–178.
- 13 Kacířová, I. – Grundmann, M.: Trend analysis of the utilization of antiepileptic drugs in pregnant women with epilepsy in Moravian-Silesian region of the Czech Republic. *Klin Farmakol Farm*, 2016, 30, s. 23–28.
- 14 Kacířová, I. – Grundmann, M. – Broznanová, H.: Serum levels of lamotrigine during delivery in mothers and their infants. *Epilepsy Res*, 2010, 91, s. 161–165.
- 15 Kacířová, I. – Grundmann, M. – Broznanová, H.: Serum levels of valproic acid during delivery in mothers and in umbilical cord – correlation with birth length and weight. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2015, 159, s. 569–575.
- 16 Kacířová, I. – Grundmann, M. – Broznanová, H.: Concentrations of carbamazepine and carbamazepine-10,11-epoxide in maternal and umbilical cord blood at birth: Influence of co-administration of valproic acid or enzyme-inducing antiepileptic drugs. *Epilepsy Res*, 2016, 122, s. 84–90.
- 17 Budakova, L. – Broznanova, H. – Grundmann, M. – Fischer, J.: Simultaneous determination of antiepileptic drugs and two active metabolites by HPLC. *J Separ Sci*, 2008, 31, s. 1–8.
- 18 Johnson, E. L. – Stowe, Z. N. – Ritchie, J. C., et al.: Carbamazepine clearance and seizure stability during pregnancy. *Epilepsy Behav*, 2014, 33, s. 49–53.
- 19 Kacířová, I. – Grundmann, M.: Terapeutické monitorování hladin antiepileptik II. – „nová“ antiepileptika, speciální skupiny pacientů. *Klin Farmakol Farm*, 2016, 30, s. 16–22.
- 20 Grundmann, M. – Kacířová, I.: Terapeutické monitorování hladin antiepileptik I. – obecné zásady, „stará“ antiepileptika. *Klin Farmakol Farm*, 2016, 30, s. 9–15.
- 21 Meador, K. J. – Baker, G. A. – Finnell, R. H., et al.: NEAD Study Group: In utero antiepileptic drug exposure: Fetal death and malformations. *Neurology*, 2006, 67, s. 407–412.
- 22 www.eurapinternational.org.
- 23 Holmes, L. B. – Mittendorf, R. – Shen, A., et al.: Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. *Arch Neurol*, 2011, 68, s. 1275–1281.
- 24 Tomson, T. – Battino, D.: Teratogenic effects of antiepileptic drugs. *Lancet Neurol*, 2012, 11, s. 803–813.

Patofyziologie migrény v roce 2018

MUDr. Rudolf Kotas, Ph.D. Neurologická klinika LF UK a FN Plzeň

- 1 Kotas, R.: *Bolest hlavy v klinické praxi*. Praha, Maxdorf, 2015.
- 2 Pietrobon, D. – Striessnig, J.: Neurobiology of migraine. *Nat Rev Neurosci*, 2003, 4, s. 386–398.
- 3 Kotas, R.: Současný pohled na patofyziologii migrény. *Cesk Slov Neurol N*, 2011, 74/107, s. 654–661.
- 4 Dussor, G. – Yan, J. – Xie, J. Y., et al.: Targeting TRP channels for novel migraine therapeutics. *Chem Neurosci*, 2014, 5, s. 1085–1096.
- 5 Benemei, S. – Fusi, C. – Trevisan, G. – Geppeti, P.: The TRPA1 channel in migraine mechanism and treatment. *Br J Pharmacol*, 2014, 171, s. 2552–2567.
- 6 Benemei, S. – De Cesaris, F. – Fusi, C., et al.: TRPA1 and other TRP channels in migraine. *J Headache Pain*, 2013, 14, s. 71.
- 7 Meents, J. E. – Beeber, L. – Reuter, U.: TRPV1 in migraine pathophysiology. *Trends Mol Med*, 2010, 16, s. 153–159.
- 8 Zhang, X. C. – Strassman, A. M. – Novack, V., et al.: Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels. Are we getting closer to solving this puzzle? *Cephalalgia*,

- 2016, 36, s. 875–886.
- Diener, H. Ch. – Charles, A. – Goadsby, P. J., et al.: New therapeutic approaches for the prevention and treatment of migraine. *Lancet Neurol*, 2015, 14, s. 1010–1022.
 - Dodick, D. W. – Turkel, C. C. – De Grise, R. E., et al.: PREEMT Chronic Migraine Study Group: Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMT clinical program. *Headache*, 2010, 50, s. 921–936.
 - Lipton, R. B. – Varon, S. F. – Grosberg, B., et al.: Onabotulinumtoxin A improves quality of life and reduces impact of chronic migraine. *Neurology*, 2011, 77, s. 1465–1472.
 - Brandes, J. – Diener, H. Ch. – Dolezil, D., et al.: Chronic migraine treatment with erenumab: responder rates. *Cephalalgia*, 2017, 37, suppl. 1, s. 36.
 - Aycardi, E. – Bigal, M. – Yeung, P., et al.: Efficacy and safety of 2 dose regimens of subcutaneous administration of fremanezumab (TEV-48125) versus placebo for the preventive treatment of episodic migraine. *Cephalalgia*, 2017, 37, suppl. 1, s. 343.
 - Detke, H. C. – Wang, Sh. – Skljarevski, V., et al.: A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine. Results from the 3-month double-blind treatment phase of the REGAIN study. *Cephalalgia*, 2017, 37, suppl. 1, s. 338.
 - Goadsby, P. J. – Smith, J. – Dodick, D., et al.: Migraine prevention benefits of ALD 403 (eptinezumab) begin in the first 24 hours following intravenous administration. *Cephalalgia*, 2017, 37, suppl. 1, s. 38–39.
 - Tepper, S. J. – Diener, H.-Ch. – Ashina, M., et al.: Efficacy of erenumab for the treatment of patients with chronic migraine in presence of medication overuse. *Cephalalgia*, 2017, 37, suppl. 1, s. 33–34.
 - Ashina, M. – Tepper, S. – Brandes, J. L., et al.: Efficacy of erenumab (a fully human Mab targeting the CGRP receptor) in chronic migraine patients with prior treatment failure: a subgroup analysis of the phase 2, randomized, double-blind, placebo-controlled study. *Cephalalgia*, 2017, 37, suppl. 1, s. 326–327.
 - Deen, M. – Correnti, E. – Kamm, K., et al.: European Headache Federation School of Advanced Studies (EHF-SAS): Blocking CGRP in migraine patients – a review of pros and cons. *J Headache Pain*, 2017, 18, s. 96.
 - Vollesen, A. L. H. – Amin, F. M. – Ashina, M.: Targeted pituitary adenylate cyclase-activating peptide therapies for migraine. *Neurotherapeutics*, 2018, 15, s. 371–376.
 - Ashina, H. – Guo, S. – Vollesen, A. L. H., et al.: PACAP38 in human models of primary headaches. *J Headache Pain*, 2017, 18, s. 110.
 - Edvinsson, L. – Tajti, J. – Szalárdy, L. – Vécsei, L.: PACAP and its role in primary headaches. *J Headache Pain*, 2018, 19, s. 21.
 - Ashina, M. – Martelletti, P.: Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches? *J Headache Pain*, 2018, 19, s. 33.

Reverzibilita mechanismu účinku u roztroušené sklerózy

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- Pardo, G. – Jones, D. E.: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. *J Neurol*, 2017, 264, s. 2351–2374.
- Physician Information and Management Guidelines for Multiple Sclerosis Patients on TYSABRI Therapy (Version 16). Dostupné z: [https://www.hpriaie/docs/default-source/3rd-party-documents/tysabri-physician-information-and-management-guidelines-\(version-15-27th-april-2016\).pdf?sfvrsn=2](https://www.hpriaie/docs/default-source/3rd-party-documents/tysabri-physician-information-and-management-guidelines-(version-15-27th-april-2016).pdf?sfvrsn=2), vyhledáno 29. 11. 2019.
- Butzkueven, H. – Kappos, L. – Pellegrini, F., et al.: Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. *J Neurol Neurosurg Psychiatry*, 2014, 0, s. 1–8.

Postavení nových perorálních antikoagulantů u invazivních nebo chirurgických výkonů

doc. MUDr. Tomáš Kvasnička, CSc. Trombotické centrum, ÚLBDL VFN a LF UK, Praha

- Koscielny, J. – Rosenthal, C. – von Heymann, C.: Update on Direct Oral Anti Coagulants (DOACs). *Phlebologie*, 2018, 3, s. 137–145.
- Olesen, J. B. – Torp-Pedersen, C. – Hansen, M. L., et al.: The value of the CHA₂DS₂-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS₂ score 0–1: a nation wide cohort study. *Thromb Haemost*, 2012, 107, s. 1172–1179.
- Kirchhof, P. – Benussi, S. – Kotecha, D., et al.: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*, 2016, 37, s. 2893–2962.
- Whitlock, R. P. – Sun, J. C. – Frenes, S. E., et al.: Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, 2012, 141, s. e5765–e6005.
- Douketis, J. D. – Spyropoulos, A. C. – Spencer, F. A., et al.: Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*, 2012, 141, s. e3265–e3505.
- Pengo, V. – Ruffatti, A. – Legnani, C., et al.: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. *J Thromb Haemost*, 2010, 8, s. 237–242.
- Torn, M. – Rosendaal, F. R.: Oral anticoagulation in surgical procedures: risks and recommendations. *Br J Haematol*, 2003, 123, s. 676–682.
- Siegel, D. M. – Crowther, M. A.: Acute management of bleeding in patients on novel oral anticoagulants. *Eur Heart J*, 2013, 34, s. 489–500.
- Kvasnička, T. – Malíková, I. – Zenáhlíková, Z., et al.: Rivaroxaban – metabolism, pharmacologic properties and drug interactions. *Current Drug Metab*, 2017, 18, s. 636–642.
- Ortel, T. L.: Perioperative management of patients on chronic anti-thrombotic therapy. *Hematol Am Soc Hematol Educ Program*, 2012, s. 529–535.
- Spyropoulos, A. C. – Douketis, J. D.: How I treat anti-coagulated patients under going an elective procedure or surgery. *Blood*, 2012, 120, s. 2954–2962.
- Baglin, T. – Hillarp, A. – Tripodi, A., et al.: Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost*, 2013, 11, s. 756–760.

Porovnání klinického efektu převodu z Warfarinu Orion 3 mg na Warfarin PMCS 2 mg/5 mg

MUDr. Petr Magrot Ambulance OKB Lab, a. s., Praha

- Gao, D. – Maurin, M. B.: Physical chemical stability of warfarin sodium. *AAPS Pharm Sci*, 2001, 3, s. 1–8.
- Kopecký – Zoulová: Warfarin (srovnání warfarinu sodného a warfarinu sodného klatrátu), vyhledáno 12. 8. 2016.
- Souhřn údajů o přípravku Warfarin PMCS 2 mg, Warfarin PMCS 5 mg tablety, sp. zn. suklS 218737/2016.
- Souhřn údajů o přípravku Warfarin Orion 3 mg, Warfarin Orion 5 mg tablety, sp. zn. suklS 221027/2016.
- Pecka, M.: *Laboratorní hematologie v přehledu. Fyziologie a patofyziologie hemostázy*. Český Těšín, Finiur, 2004, s. 214–216.
- Magrot, P. – Hrdličková, L.: Porovnání klinického efektu Warfarinu PMCS vůči Warfarinu Orion. *Acta Medica*, 2017, 11, s. 48–51.

Lercanidipin: příznivé farmakologické vlastnosti jako předpoklad terapeutické účinnosti, bezpečnosti a vysoké compliance nemocných

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Angelico, P. – Guarneri, L. – Leonardi, A., et al.: Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. *J Pharm Pharmacol*, 1999, 51, s. 709–714.
- Guarneri, L. – Angelico, P. – Ibba, M., et al.: Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. *Arzneimittelforschung*, 1996, 46, s. 15–24.
- van Zwieten, P. A.: The pharmacological properties of lipophilic calcium antagonists. *Blood Press Suppl*, 1998, 2, s. 5–9.
- Cerbaj, E. – Sartiani, L. – DePaoli, P., et al.: Electrophysiologic effects of lercanidipine on repolarizing potassium currents. *J Cardiovasc Pharmacol*, 2000, 36, s. 584–591.
- Corsini, A. – Accomazzo, M. R. – Canavesi, M., et al.: The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? *Blood Press Suppl*, 1998, 2, s. 18–22.
- Soma, M. R. – Natali, M. – Donetti, E., et al.: Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. *Br J Pharmacol*, 1998, 125, s. 1471–1476.
- Lin, T. H. – Voon, W. C. – Yen, H. W., et al.: Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters. *Kaohsiung J Med Sci*, 2006, 22, s. 177–183.
- Sasaki, T. – Maruyama, H. – Kase, Y., et al.: Antianginal effects of lercanidipine on the vasopressin or methacholine induced anginal model in rats. *Biol Pharm Bull*, 2005, 28, s. 811–816.
- Sakurai-Yamashita, Y. – Harada, N. – Niwa, M.: Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. *Cell Mol Neurobiol*, 2011.
- Sonkusare, S. – Srinivasan, K. – Kaul, C., et al.: Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. *Life Sci*, 2005, 77, s. 1–14.
- Cheng, K. H. – Cheng, K. C. – Cheng, K. Y., et al.: Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. *Curr Med Res Opin*, 2017, 33, s. 1111–1117.
- Cominacini, L. – Fratta, P. A. – Garbin, U., et al.: Antioxidant activity of different dihydropyridines. *Biochem Biophys Res Commun*, 2003, 302, s. 679–684.
- Sabbatini, M. – Tomassoni, D. – Di Tullio, M. A., et al.: Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. *Clin Exp Hypertens*, 2002, 24, s. 727–740.
- Marcal, D. M. – Rizzi, E. – Martins-Oliveira, A., et al.: Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. *Naunyn-Schmiedeberg Arch Pharmacol*, 2011, 383, s. 35–44.
- Alvarez, C. – Gomez, E. – Simon, M., et al.: Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake. *Eur J Clin Pharmacol*, 2012.

- 16 Bang, L. M. – Chapman, T. M. – Goa, K. L.: Lercanidipine: a review of its efficacy in the management of hypertension. *Drugs*, 2003, 63, s. 2449–2472.
- 17 Romito, R. – Pansini, M. I. – Perticone, F., et al.: Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. *J Clin Hypertens* (Greenwich), 2003, 5, s. 249–253.
- 18 Barrios, V. – Escobar, C. – de la Figuera, M., et al.: Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. *Cardiovasc Ther*, 2008, 26, s. 2–9.
- 19 Leonetti, G. – Magnani, B. – Pessina, A. C., et al.: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. *Am J Hypertens*, 2002, 15, s. 932–940.
- 20 Borghi, C. – Prandini, M. G. – Dormi, A., et al.: Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. *Blood Press*, 2003, 12, suppl. 1, s. 14–21.
- 21 Makarounas-Kirchmann, K. – Glover-Koudounas, S. – Ferrari, P.: Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. *Clin Ther*, 2009, 31, s. 1652–1663.
- 22 Cerbai, E. – Mugelli, A.: Lercanidipine and T-type calcium current. *Eur Rev Med Pharmacol Sci*, 2018, 22, s. 4025–4031.
- 23 Grassi, G. – Robles, N. R. – Seravalle, G., et al.: Lercanidipine in the management of hypertension: an update. *J Pharmacol Pharmacother*, 2017, 8, s. 155–165.
- 24 Barrios, V. – Escobar, C. – de la Figuera, M., et al.: High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. *Int J Clin Pract*, 2008, 62, s. 723–728.

Fixní kombinace perindoprilu, amlodipinu a indapamidu

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Salvetti, A.: Newer ACE inhibitors. A look at the future. *Drugs*, 1990, 40, s. 800–828.
- 2 Harder, S. – Thurmann, P. A. – Ungethüm, W.: Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. *Br J Clin Pharmacol*, 1998, 45, s. 377–380.
- 3 Su, J. B. – Barbe, F. – Crozatier, B., et al.: Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. *J Cardiovasc Pharmacol*, 1999, 34, s. 700–710.
- 4 Eichstadt, H. W. – Felix, R. – Langer, M., et al.: Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment. *Am J Cardiol*, 1987, 59, s. 98D–103D.
- 5 Mulder, P. – Devaux, B. – el Fertak, L., et al.: Vascular and myocardial protective effects of converting enzyme inhibition in experimental heart failure. *Am J Cardiol*, 1995, 76, s. 28E–33E.
- 6 Jeserich, M. – Pape, L. – Just, H., et al.: Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure. *Am J Cardiol*, 1995, 76, s. 1079–1082.
- 7 Zhuo, J. L. – Mendelsohn, F. A. – Ohishi, M.: Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. *Hypertension*, 2002, 39, s. 634–638.
- 8 Abernethy, D. R.: Pharmacokinetics and pharmacodynamics of amlodipine. *Cardiology*, 1992, 80, suppl. 1, s. 31–36.
- 9 Robinson, D. M. – Wellington, K.: Indapamide sustained release: a review of its use in the treatment of hypertension. *Drugs*, 2006, 66, s. 257–271.
- 10 Ambrosioni, E. – Safar, M. – Degaute, J. P., et al.: Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. *J Hypertens*, 1998, 16, s. 1677–1684.
- 11 Emriau, J. P. – Knauf, H. – Pujadas, J. O., et al.: A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. *J Hypertens*, 2001, 19, s. 343–350.
- 12 Bataillard, A. – Schiavi, P. – Sassard, J.: Pharmacological properties of indapamide. Rationale for use in hypertension. *Clin Pharmacokinet*, 1999, 37, suppl. 1, s. 7–12.
- 13 Macfadyen, R. J. – Lees, K. R. – Reid, J. L.: Perindopril. A review of its pharmacokinetics and clinical pharmacology. *Drugs*, 1990, 39, suppl. 1, s. 49–63.
- 14 Devissaguet, J. P. – Ammoury, N. – Devissaguet, M., et al.: Pharmacokinetics of perindopril and its metabolites in healthy volunteers. *Fundam Clin Pharmacol*, 1990, 4, s. 175–189.
- 15 Abernethy, D. R.: The pharmacokinetic profile of amlodipine. *Am Heart J*, 1989, 118, s. 1100–1103.
- 16 Elijovich, F. – Laffer, C.: A role for single-pill triple therapy in hypertension. *Ther Adv Cardiovasc Dis*, 2009, 3, s. 231–240.
- 17 Neutel, J. M. – Smith, D. H.: Hypertension management: rationale for triple therapy based on mechanisms of action. *Cardiovasc Ther*, 2013, 31, s. 251–258.
- 18 Mancía, G. – Fagard, R. – Narkiewicz, K., et al.: 2013 ESH/ESC practice guidelines for the management of arterial hypertension. *Blood Press*, 2014, 23, s. 3–16.
- 19 Weber, M. A. – Schiffrin, E. L. – White, W. B., et al.: Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens*, 2014, 32, s. 3–15.
- 20 Piepoli, M. F. – Hoes, A. W. – Agewall, S., et al.: 2016 European guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*, 2016, 37, s. 2315–2381.
- 21 PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet*, 2001, 358, s. 1033–1041.
- 22 Patel, A. – MacMahon, S. – Chalmers, J., et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*, 2007, 370, s. 829–840.
- 23 Dahlof, B. – Gosse, P. – Gueret, P., et al.: Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. *J Hypertens*, 2005, 23, s. 2063–2070.
- 24 Beckett, N. S. – Peters, R. – Fletcher, A. E., et al.: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–1898.
- 25 Dahlof, B. – Sever, P. S. – Poulter, N. R., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*, 2005, 366, s. 895–906.
- 26 Radchenko, G. D. – Mushtenko, L. O. – Sirenko, Y. M.: Influence of fixed-dose combination perindopril/amlodipine on target organ damage in patients with arterial hypertension with and without ischemic heart disease (results of EPHES trial). *Vasc Health Risk Manag*, 2018, 14, s. 265–278.
- 27 Toth, K.: Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiovasc Drugs*, 2014, 14, s. 137–145.
- 28 Pall, D. – Szanto, I. – Szabo, Z.: Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. *Clin Drug Invest*, 2014, 34, s. 701–708.
- 29 Nedogoda, S. V. – Stojanov, V. J.: Single-pill combination of perindopril/indapamide/amlodipine in patients with uncontrolled hypertension: a randomized controlled trial. *Cardiol Ther*, 2017, 6, s. 91–104.
- 30 Mourad, J. J. – Amodeo, C. – de Champvallins, M., et al.: Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. *J Hypertens*, 2017, 35, s. 1481–1495.
- 31 Abraham, G. – Dezi, C. A.: The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: the results of the PETRA study. *Adv Ther*, 2017, 34, s. 1753–1763.
- 32 Makani, H. – Bangalore, S. – Romero, J., et al.: Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. *Am J Med*, 2011, 124, s. 128–135.
- 33 Fogari, R. – Zoppi, A. – Tettamanti, F., et al.: Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. *J Cardiovasc Pharmacol*, 1992, 19, s. 670–673.

Význam eozinofilů jako diagnostického a prediktivního biomarkeru; algoritmy léčby těžkého astmatu v době personalizované medicíny

doc. MUDr. Jaromír Bystrůň, CSc. Oddělení alergologie a klinické imunologie FN Olomouc

- 1 Wenzel, S. E.: Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med*, 2012, 18, s. 716–725, doi: 10.1038/nm.2678. Review.
- 2 Braido, F. – Tiotiu, A. – Kowal, K., et al.: Phenotypes/endotypes-driven treatment in asthma. *Curr Opin Allergy Clin Immunol*, 2018, 18, s. 184–189.
- 3 Opina, M. T. – Moore, W. C.: Phenotype-driven therapeutics in severe asthma. *Curr Allergy Asthma Rep*, 2017, 17, s. 10.
- 4 Casio, B. G. – Perezde Llano, L. – Lopez Vina, A., et al.: Th-2 signature in chronic airway diseases: towards the extinction of Asthma-COPD overlap syndrome? *Eur Resp J*, 2017, 49, pii:1602397.
- 5 Seys, S. F. – Scheers, H. – Van den Brande, P., et al.: Cluster analysis of sputum cytokine-high profiles reveals diversity in Th2-high asthma patients. *Resp Res*, 2017, 18, s. 39.
- 6 Bystrůň, J. – Heller, L. – Ostrčilová, H., et al.: Přspěvek k etiologii, klasifikaci a léčbě těžkého průduškového astmatu. *Alergie*, 2010, 12, s. 173–178.
- 7 Turner, S. – Paton, J. M. – Higgins, B. – Douglas, G.: British guidelines on the management of asthma: what's new for 2011? *Thorax*, 2011, 66, s. 1104–1105.
- 8 Fairbairn, S.: Current opinion in allergy and clinical immunology: a change in leadership. *Curr Opin Allergy Clin Immunol*, 2018, 18, s. 167.

Cefprozil versus klarithromycin v léčbě exacerbace chronické bronchitidy

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Saint, S. – Bent, S. – Vittinghoff, E., et al.: Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. *JAMA*, 1995, 273, s. 957–960.
- 2 Vollenweider, D. J. – Jarrett, H. – Steurer-Stey, C. A., et al.: Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, 2012, 12, CD010257.
- 3 Vollenweider, D. J. – Frei, A. – Steurer-Stey, C. A., et al.: Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, 2018, 10, CD010257.
- 4 Bonnet, J. P. – Ginsberg, D. – Nolen, T.: Cefprozil vs. cefuroxime axetil in mild to moderate lower respiratory tract infections: a focus on bronchitis. *Infect Med*, 1992, 9, s. 48.
- 5 Puopolo, A. L. – Kennard, M. J. – Mallatratt, L., et al.: A randomized, multicenter, comparative trial of cefprozil and cefuroxime axetil in the treatment of acute bacterial bronchitis and AECB. *Infect Med*, 1997, 14, s. 51–59.
- 6 Sappington, R. F.: A multicenter study of cefprozil vs clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis.

Infect Med, 1997, 14, s. 61–68.

7 **Bishai, W. R.**: Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin. *Expert Rev Anti Infect Ther*, 2006, 4, s. 405–416.

8 **Gotfried, M. – Busman, T. A. – Norris, S., et al.**: Role for 5-day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis. *Curr Med Res Opin*, 2007, 23, s. 459–466.

9 **McCarty, J. M. – Pierce, P. F.**: Five days of cefprozil versus 10 days of clarithromycin in the treatment of an acute exacerbation of chronic

bronchitis. *Ann Allergy Asthma Immunol*, 2001, 87, s. 327–334.

10 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of chronic obstructive pulmonary disease: 2018 Report. Dostupné z: <http://www.goldcopd.org>, vyhledáno 20. 4. 2018.

Studie ACTIVATE: účinek acilidinium/formoterolu na plicní hyperinflaci, výkonnost a fyzickou aktivitu u pacientů s chronickou obstrukční plicní nemocí

MUDr. Zuzana Perná Plicní ambulance, Medicon a.s., Praha

1 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017, www.goldcopd.org.

2 Global Strategy for Diagnosis, Management and Prevention of COPD, (GOLD), 2018, www.goldcopd.org.

3 **Vogelmeier, C. F. – Criner, G. J. – Martinez, F. J., et al.**: Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. *Eur Respir J*, 2017, 49, s. 1700214.

4 **Watz, H. – Pitta, F. – Rochester, C. L., et al.**: An official European

Respiratory Society statement on physical activity in COPD. *Eur Respir J*, 2014, 44, s. 1521–1537.

5 **Watz, H. – Waschki, B. – Meyer, T., et al.**: Physical activity in patients with COPD. *Eur Respir J*, 2009, 33, s. 262–272.

6 **Koblížek, V., et al.**: Doporučený postup pro diagnostiku a léčbu stabiální CHOPN. ČPFS, 2013, www.pneumologie.cz.

7 **Bártů, V.**: Nová duální kombinace acilidinium bromidu a formoterol fumarátu. *Remedia*, 2015, 6, s. 392–394.

8 **Troosters, T. – Bourbeau, J. – Maltais, F., et al.**: Enhancing exercise tolerance and physical activity in COPD with combined pharmacological

and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. *BMJ Open*, 2016, 6, e010106.

9 **Maltais, F. – Celli, B. – Casaburi, R., et al.**: Acilidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. *Respir Med*, 2011, 105, s. 580–587.

10 **Mendoza, L. – Horta, P. – Espinoza, J., et al.**: Pedometers to enhance physical activity in COPD: a randomised controlled trial. *Eur Respir J*, 2015, 45, s. 347–354.

Farmakologická léčba hyperaktivního močového měchýře

MUDr. Alexandra Gregušová | MUDr. Zuzana Kachlířová Urologická klinika 3. LF UK a FN Královské Vinohrady, Praha

1 **Kachlířová, Z. – Horčíčka, L.**: Hyperaktivní močový měchýř – možnosti léčby v roce 2012. *Remedia*, 2012. Dostupné z: www.remmedia.cz.

2 **Gacci, M. – Sebastianelli, A. – Spatafora, P., et al.**: Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. *Ther Adv Urol*, 2018, 10, s. 79–92.

3 **Hegde, S. S.**: Muscarinic receptors in the bladder: from basic research

to therapeutics. *Br J Pharmacol*, 2006, 147, suppl. 2, s. 80–87.

4 **Stamm, A. W. – Adelstein, S. A. – Chen, A., et al.**: Inconsistency in the definition of urinary tract infection after intravesical botulinum toxin A injection: a systematic review. *J Urol*, 2018, pii: S0022-5347(18)42924-42922.

5 **Freeman, R. – Foley, S. – Rosa Arias, J., et al.**: Mirabegron improves

quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. *Curr Med Res Opin*, 18. 12. 2017, s. 1–9.

6 **Krhut, J.**: *Hyperaktivní močový měchýř*. Praha, Maxdorf, 2007.

7 **Mašata, J.**: Anticholinergní látky v léčbě hyperaktivního močového měchýře. *Remedia*, 2007, 17, s. 89–100.

Léčba Pompeho nemoci

doc. MUDr. Martin Magner, Ph.D. | MUDr. Jitka Jirečková Klinika dětského a dorostového lékařství, 1. LF UK a VFN, Praha

1 **Anderson, L. J. – Henley, W. – Wyatt, K. M., et al.**: Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. *J Inherit Metab Dis*, 2014, 37, s. 945–952.

2 **Bijvoet, A. G. – van de Kamp, E. H. – Kroos, M. A., et al.**: Generalized glycogen storage and cardiomegaly in knockout mouse model of Pompe disease. *Hum Mol Genet*, 1998, 7, s. 53–62.

3 **Douillard-Guilloux, G. – Raben N. – Takikita, S., et al.**: Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. *Hum Mol Genet*, 2008, 15, 17, s. 3876–3886.

4 **Kishnani, P. S. – Hwu, W. L. – Mandel, H., et al.**: Infantile-Onset Pompe Disease Natural History Study. G. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. *J Pediatr*, 2006, 148, s. 671–676.

5 **Kishnani, P. S. – Corzo, D. – Nicolino, M., et al.**: Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology*, 2007, 68, s. 99–109.

6 **Kishnani, P. S. – Goldenberg, P. C. – DeArme, S. L., et al.**: Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. *Mol Genet Metab*, 2010, 99, s. 26–33.

7 **Magner, M. – Honzík, T. – Zeman, J.**: Pompeho nemoc (glykogenóza

typu II). In: Honzík, T. – Zeman, T.: *Dědičné poruchy metabolismu v kazuistikách*. Mladá Fronta, 2016.

8 **Magner, M. – Jirečková, J.**: Pompeho nemoc. *Neurologie pro praxi*, 2018, 19, s. 224–227.

9 **Müller-Felber, W. – Horvath, R. – Gempel, K., et al.**: Late onset Pompe disease: clinical and neuropsychological spectrum of 38 patients including long-term follow-up in 18 patients. *Neuromuscul Disord*, 2007, 17, s. 698–706.

10 **Parenti, G. – Andria, G.**: Pompe disease: from new views on pathophysiology to innovative therapeutic strategies. *Curr Pharm Biotechnol*, 2011, 12, s. 902–915.

11 **Prater, S. N. – Banugaria, S. G. – DeArme, S. M., et al.**: The emerging phenotype of long-term survivors with infantile Pompe disease. *Genet Med*, 2012, 14, s. 800–810.

12 **Regnery, C. – Kornblum, C. – Hanisch, F., et al.**: 36 months observational clinical study of 38 adult Pompe disease patients under alpha-glucosidase alpha enzyme replacement therapy. *J Inherit Metab Dis*, 2012, 35 (5), s. 837–845.

13 **Smith, B. K. – Martin, A. D. – Lawson, L. A., et al.**: 2017 Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity. *Exp Neurol*, 2017, 287, s. 216–224.

14 **Thurberg, B. L. – Lynch Maloney, C. – Vaccaro, C., et al.**: Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. *Lab Invest*, 2006, 86, s. 1208–1220.

15 **Toscano, A. – Montagnese, F. – Musumeci, O.**: Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD). *Acta Myol*, 2013, 32, s. 78–81.

16 **van den Hout, J. M. – Kamphoven, J. H. – Winkel, L. P., et al.**: Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. *Pediatrics*, 2004, 113, s. 448–457.

17 **van den Hout, H. – Reuser, A. J. – Vulto, A. G., et al.**: Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. *Lancet*, 2000, 356, s. 397–398.

18 **van der Beek, N. A. – de Vries, J. M. – Hagemans, M. L.**: Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. *Orphanet J Rare Dis*, 2012, 7, s. 88.

19 **van der Ploeg, A. T. – Reuser, A. J.**: Pompe's disease. *Lancet*, 2008, 11, 372, s. 1342–1353.

20 **Winkel, L. P. – van den Hout, J. M. – Kamphoven, J. H., et al.**: Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. *Ann Neurol*, 2004, 55, s. 495–502.

Konzervativní léčba glaukomu

doc. MUDr. Eva Růžičková, CSc. Oční klinika 1. LF UK a VFN, Praha

1 **Růžičková, E.**: *Glaukom*. Maxdorf, Praha, 2006, s. 36–67.

2 **European Glaucoma Society**: *Terminology and Guidelines for Glaucoma*. Dogma, Savona, Itálie, 2003, kapitola 3.

3 **Šebesta, P.**: *Konzervativní terapie glaukomu*. Kolektiv autorů Oční klinika 1. LF UK a ÚVN v Praze, Glaukom – vybrané kapitoly, Nucleus HK,

Hradec Králové, 2008, s. 133–156.

4 **Škop, B.**: *Mikro-verze AISLP*. ČR, Praha, 2008.

5 **Gandolfi, S. A. – Sangermani, C. – Cimino, L., et al.**: Is there a non IOP-related effect of brimonidine on visual field progression in human glaucoma? Prezentováno na Annual Meeting of the Association

for Research in Vision and Ophthalmology (ARVO), 25.–29. 4. 2004, Fort Lauderdale, FL.

6 SPC přípravku Bimatoprost/timolol PharmaSwiss, www.sukl.cz.